Skip to main content
Show — Main navigation Hide — Main navigation
  • Home
  • About
    • The Chair
    • Inquiry Team
    • Expert Groups
    • Inquiry Intermediaries
    • Core Participants
    • Legal Representatives
    • Financial Reports
  • Approach
    • Terms of reference
    • List of Issues
    • Statements of approach
    • Inquiry Principles
  • News
    • News
    • Newsletter Archive
  • Reports
    • Compensation Framework Study
    • First Interim Report
    • Second Interim Report
    • The Inquiry Report
  • Publication Day
  • Evidence
    • Evidence
    • Hearings Archive
  • Compensation
  • Support
    • Confidential Psychological Support
    • Interim Payments
    • Support Groups
    • Get in touch
    • Infected Blood Support Schemes
    • Treatment and aftercare
    • Medical Evidence
    • Expenses Guidance
Accessibility Tool
  • Zoom in
  • Zoom out
  • Reset
  • Contrast
  • Accessibility tool
Get in touch

Quick Exit

Dr John Cash established the SNBTS Coagulation Factor Study Group.

  • Read more about Dr John Cash established the SNBTS Coagulation Factor Study Group.

Dr Peter Foster was shocked when Dr John Cash told him that the German company Behringwerke had announced at a symposium in Bonn that it was pasteurising Factor 8, as he had thought heat could not be used to inactivate virus in factor products.

  • Read more about Dr Peter Foster was shocked when Dr John Cash told him that the German company Behringwerke had announced at a symposium in Bonn that it was pasteurising Factor 8, as he had thought heat could not be used to inactivate virus in factor products.

Milt Mozen visited SNBTS PFC and discussed the issue of hepatitis with Jim Smith.

  • Read more about Milt Mozen visited SNBTS PFC and discussed the issue of hepatitis with Jim Smith.

A clinical trial of 8Y was reported to be at a stage where several patients had safely passed the point at which first evidence of non-A non-B Hepatitis transmission would have been expected.

  • Read more about A clinical trial of 8Y was reported to be at a stage where several patients had safely passed the point at which first evidence of non-A non-B Hepatitis transmission would have been expected.

J K Smith, Lowell Winkelman and P A Feldman reported the interim results that severe heating had been more effective in preventing transmission of non-A non-B Hepatitis than the milder heating given to at least two US commercial products.

  • Read more about J K Smith, Lowell Winkelman and P A Feldman reported the interim results that severe heating had been more effective in preventing transmission of non-A non-B Hepatitis than the milder heating given to at least two US commercial products.

Dr Shanbrom had suggested to the executives that they should no longer take plasma from hepatitis hotspots such as downtown Los Angeles and from prisons because of the risks.

  • Read more about Dr Shanbrom had suggested to the executives that they should no longer take plasma from hepatitis hotspots such as downtown Los Angeles and from prisons because of the risks.

Clive Collins stated that ,"Given the specialised medical nature of the seroconversion problem it was appropriate that my Medical Department colleagues dealt directly with the DHSS Medical staff."

  • Read more about Clive Collins stated that ,"Given the specialised medical nature of the seroconversion problem it was appropriate that my Medical Department colleagues dealt directly with the DHSS Medical staff."

Dr Peter Fernandes stated that similar stabilisers to those which worked with the globulin could work with antihemophilic factor.

  • Read more about Dr Peter Fernandes stated that similar stabilisers to those which worked with the globulin could work with antihemophilic factor.

Dr Milton Mozen, the director of biochemical research and development at Cutter, emphasised in his evidence to the Institute of Medicine in the US that a heat treatment process is successful as applied by one manufacturer, it does not follow that this process would be applicable to the unique products of the other manufacturer.

  • Read more about Dr Milton Mozen, the director of biochemical research and development at Cutter, emphasised in his evidence to the Institute of Medicine in the US that a heat treatment process is successful as applied by one manufacturer, it does not follow that this process would be applicable to the unique products of the other manufacturer.

Some Factor 8 product had been recalled, but this was probably a batch recall rather than a general recall.

  • Read more about Some Factor 8 product had been recalled, but this was probably a batch recall rather than a general recall.

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 208
  • Page 209
  • Page 210
  • Page 211
  • Current page 212
  • Page 213
  • Page 214
  • Page 215
  • Page 216
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to

Inquiry

  • Home
  • About
  • Approach
  • Participate
  • News
  • Evidence
  • Support
  • Get in touch

Legal

  • Terms & Conditions
  • Cookies notice
  • Privacy Notice
  • Accessibility tool

Address

Infected Blood Inquiry
5th Floor
Aldwych House
71-91 Aldwych
London
WC2B 4HN
 
Images of individuals on the website are used with the agreement of those featured or are stock images.

Follow us

© Crown copyright. Licensed under the Open Government Licence v3.0 except where otherwise stated.